Evidence method
Level · gp.fundamentals.debt_to_revenue
425.56% · OPTIONAL · NOT_ENOUGH_HISTORY
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME
SPRY · Mar 31, 2026
ARS Pharmaceuticals, Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.
STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration
State dimensions
Filing0001193125-26-225142General Corporate
Evidence method
Level · gp.fundamentals.capex_revenue_ratio
0.00% · OPTIONAL · NOT_ENOUGH_HISTORY
Evidence method
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
-198.17% · OPTIONAL · NOT_ENOUGH_HISTORY
Evidence method
Yoy · gp.fundamentals.revenue
184.47% · CORE · NOT_ENOUGH_HISTORY
Evidence method
Level · gp.fundamentals.inventory_revenue_ratio
141.25% · OPTIONAL · NOT_ENOUGH_HISTORY
Evidence method
Level · gp.fundamentals.operating_margin
-265.18% · CORE · NOT_ENOUGH_HISTORY
Evidence method
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
19.12% · OPTIONAL · NOT_ENOUGH_HISTORY
Evidence method
Level · gp.fundamentals.sbc_revenue_ratio
32.73% · OPTIONAL · NOT_ENOUGH_HISTORY
As-filed lineage
Fundamental state history
Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History4 statesHistory building
Period transition
What moved in the state?
- Previous
- 114.35%
- Current
- 425.56%
- Delta
- 311.21%
- Previous
- 0.40%
- Current
- 0.00%
- Delta
- -0.40%
- Previous
- -202.74%
- Current
- -198.17%
- Delta
- 4.58%
- Previous
- -5.46%
- Current
- 184.47%
- Delta
- 189.94%
- Previous
- 37.28%
- Current
- 141.25%
- Delta
- 103.97%
- Previous
- -212.92%
- Current
- -265.18%
- Delta
- -52.25%
- Previous
- 15.64%
- Current
- 19.12%
- Delta
- 3.48%
- Previous
- 26.22%
- Current
- 32.73%
- Delta
- 6.51%
Self-history only
Previous similar states
Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research
Has State · ARS Pharmaceuticals, Inc. →Transitioned To · SPRY Fundamental State →Transitioned To · SPRY BALANCE_SHEET_LEVERAGE_INCREASED →Transitioned To · SPRY CAPEX_INTENSITY_DECREASED →Transitioned To · SPRY CASH_GENERATION_INCREASED →Transitioned To · SPRY GROWTH_INCREASED →Transitioned To · SPRY INVENTORY_PRESSURE_INCREASED →Transitioned To · SPRY PROFITABILITY_DECREASED →Transitioned To · SPRY R_AND_D_INTENSITY_INCREASED →Transitioned To · SPRY SBC_INTENSITY_INCREASED →
Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.